Polyplastics announces commercial availability of DURACON POM PM Series for medical industry
The company will supply materials to all global regions including Asia such as China, India, Europe, and the U.S.
The company will supply materials to all global regions including Asia such as China, India, Europe, and the U.S.
The investment is part of Croda’s continuing commitment to develop high performance pharmaceutical ingredients and technologies for life sciences.
This patent-pending, high-efficiency chromatography media is used for the purification of novel peptide-based pharmaceuticals in the GLP-1 agonist class including type 2 diabetes and obesity treatments
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
The new range of HDPE bottles is compliant with US FDA, EU regulations and Chinese DMF registration for use in dry pharmaceutical applications
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
Agreement provides customers in the majority of Europe* access to supply through Univar Solutions distribution network
New facility will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.
Subscribe To Our Newsletter & Stay Updated